BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), and AnHeart Therapeutics (“AnHeart”), today jointly announced updated efficacy and safety data from the Phase 2 TRUST clinical trial of taletrectinib in patients with ROS1-positive non-small cell lung cancer (NSCLC), at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Antengene Corporation Limited announced that Antengene has received approval by the Bellberry Human Research Ethics Committee in Australia to initiate the Phase I Trial of ATG-018 in patients with advanced solid tumors and hematologic malignancies.

scentage Pharma announced that it has released the updated results from a Phase II study of the MDM2-p53 inhibitor alrizomadlin plus pembrolizumab in adults and children with various solid tumors in a Poster Discussion session at the 58th American Society of Clinical Oncology Annual Meeting.

Franklin brings proven track record leading early commercialization and growing disruptive healthcare business models, including at Exact Sciences, Foundation Medicine and Boston Scientific.

ContraFect Corporation announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022.

Analysis shows participants who stayed in the program at least 6 months reduced their diabetes drug costs by 18%.

Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy franchises extends cash runway into 2024.

Expands BD Transformative Solutions to Provide New Pharmacy Automation Technologies for Hospitals, Retail Pharmacy, Long-Term Care and Home Settings.

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that Chief Executive Officer Diem Nguyen, Ph.D., MBA, will participate in two panels at the BIO International Convention.

Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 2022 Annual Meeting of Stockholders will be held on Thursday, June 23, 2022, at 10:00 a.m. Pacific Time.